Exchange: NSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
-1.01% INR830.90
America/New_York / 8 mai 2024 @ 05:59
FUNDAMENTALS | |
---|---|
MarketCap: | 76 359 mill |
EPS: | -16.79 |
P/E: | -49.49 |
Earnings Date: | May 23, 2024 |
SharesOutstanding: | 91.90 mill |
Avg Daily Volume: | 0.456 mill |
RATING 2024-05-08 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Buy | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Buy | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | n/a | n/a | n/a | |||
Debt | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -49.49 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -49.49 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
INR-704.65 (-184.81%) INR-1 535.55 |
Date: 2024-05-08 |
Expected Trading Range (DAY) |
---|
INR 802.65 - 859.15 ( +/- 3.40%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | INR830.90 (-1.01% ) |
Volume | 0.198 mill |
Avg. Vol. | 0.456 mill |
% of Avg. Vol | 43.48 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.